Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial
SA4Ag is a novel multi-antigen vaccine that targets S. aureus virulence factors. A single dose of SA4Ag was well-tolerated in healthy adults aged 65–85 years. A robust functional immune response was elicited to each vaccine component. Antibody rise was rapid and sustained after one dose of SA4Ag vaccine. SA4Ag is a promising candidate vaccine to prevent invasive S. aureus infections.